Citations

Clear

6273 citation(s) found for "To, Andrew".

Integrated transcriptomic and regulatory network analyses identify microRNA-200c as a novel repressor of human pluripotent stem cell-derived cardiomyocyte differentiation and maturation
Hao, Baixia , Guan, Daogang , Li, Mulin Jun , Lu, Jun, Yang, Yong , Wu, Binbin , Wu, Stanley Chun-ming, Webb, Sarah , Liang, Yan , Yao, Xiaoqiang , Wang, Junwen , Yan, Bin , Wang, Junwen , Poon, Ellen Ngar-Yun , Miller, Andrew L. , Boheler, Kenneth R.

Mayo Clinic

Cardiovascular Research | January 22, 2018 | Volume: 114 | Issue: 6 | Pages: 894-906

10.1093/cvr/cvy019 | PMID 29373717 Get It

Parasitic Infections of the Skin and Subcutaneous Tissues
Norgan, Andrew P. , Pritt, Bobbi S. , Pritt, Bobbi S , Norgan, Andrew P

Mayo Clinic

Advances in Anatomic Pathology | January 18, 2018 | Volume: 25 | Issue: 2 | Pages: 106-123

10.1097/pap.0000000000000183 | PMID 29351090 Get It

A variety of arthropods, protozoa, and helminths infect the skin and subcutaneous tissues and may be identified by anatomic pathologists in standard cytology and histology preparations. The specific organisms seen vary greatly with the patient’s exposure history, including travel to or residence in endemic countries. Arthropods are the most commonly encountered parasites in the skin and subcutaneous tissues and include Sarcoptes scabei, Demodex species, Tunga penetrans, and myiasis-causing fly larvae. Protozoal parasites such as Leishmania may also be common in some settings. Helminths are less often seen, and include round worms (eg, Dirofilaria spp.), tapeworms (eg, Taenia solium, Spirometra spp.), and flukes (eg, Schistosoma spp.). This review covers the epidemiologic and histopathologic features of common parasitic infections of the skin and subcutaneous tissues.
What are the outcomes of declining a public health service increased risk liver donor for patients on the liver transplant waiting list?
Croome, Kristopher P. , Lee, David D. , Pungpapong, Surakit , Taner, C. Burcin , Croome, Kris P , Lee, David D , Pungpapong, Surakit , Keaveny, Andrew P.

Mayo Clinic

Liver Transplantation | January 17, 2018 | Volume: 24 | Issue: 4 | Pages: 497-504

10.1002/lt.25009 | PMID 29341398 Get It

The tragedy of the national opioid epidemic has resulted in a significant increase in the number of opioid‐related deaths and accordingly an increase in the number of potential donors designated Public Health Service (PHS) increased risk. Previous studies have demonstrated reluctance to use these PHS organs, and as a result, higher discard rates for these organs have been observed. All patients listed for liver transplantation in the United States from January 2005 to December 2016 were investigated. Patients on the waiting list were divided into 2 groups: those in which a PHS liver was used for transplantation (accepted PHS group) and those in which a PHS liver was declined and transplanted into a recipient lower on the match run (declined PHS group). Intention‐to‐treat patient survival from the time of PHS offer was significantly higher in the accepted PHS compared with the declined PHS group (P < 0.001). On Cox multivariate regression, declining a PHS donor liver was associated with a hazard ratio of 2.36 (95% confidence interval, 2.23‐2.49; P < 0.001). For patients in which a PHS organ offer was declined, 11.6% died or were delisted for being too sick within the subsequent year. Donor liver allografts implanted in the accepted PHS group were of a lower donor risk index (1.28 versus 1.44) compared with the non‐PHS organs that patients in the declined PHS group ultimately received if they underwent transplantation. In conclusion, there is a significantly higher survival for patients in which a PHS liver is accepted and used compared with those patients in which a PHS organ is declined. These data will help inform decisions about whether or not to accept a PHS donor liver for both patients and transplant professionals. Liver Transplantation 24 497–504 2018 AASLD.
Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database
Rajyaguru, Devalkumar J., Borgert, Andrew J. , Smith, Angela, Thomes, R, Conway, Patrick D., Hálfdánarson, Þorvarður R. , Truty, Mark J. , Smith, Angela L, Thomes, Reggie M, Kurup, A. Nicholas , Halfdanarson, Thorvardur R , Go, Ronald S.

Mayo Clinic

Journal of Clinical Oncology | January 12, 2018 | Volume: 36 | Issue: 6 | Pages: 600-608

10.1200/jco.2017.75.3228 | PMID 29328861 Get It

Purpose Data that guide selection of optimal local ablative therapy for the management localized hepatocellular carcinoma (HCC) are lacking. Because there are limited prospective comparative data for these treatment modalities, we aimed to compare the effectiveness of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) by using the National Cancer Database. Methods We conducted an observational study to compare the effectiveness of RFA versus SBRT in nonsurgically managed patients with stage I or II HCC. Overall survival was compared by using propensity score–weighted and propensity score–matched analyses based on patient-, facility-, and tumor-level characteristics. A sensitivity analysis was performed to evaluate the effect of severe fibrosis/cirrhosis. In addition, we performed exploratory analyses to determine the effectiveness of RFA and SBRT in clinically relevant patient subsets. Results Overall, 3,684 (92.6%) and 296 (7.4%) nonsurgically managed patients with stage I or II HCC received RFA or SBRT, respectively. After propensity matching, 5-year overall survival was 29.8% (95% CI, 24.5% to 35.3%) in the RFA group versus 19.3% (95% CI, 13.5% to 25.9%) in the SBRT group ( P < .001). Inverse probability–weighted analysis yielded similar results. The benefit of RFA was consistent across all subgroups examined and was robust to the effects of severe fibrosis/cirrhosis. Conclusion Our study suggests that treatment with RFA yields superior survival compared with SBRT for nonsurgically managed patients with stage I or II HCC. Even though our results are limited by the biases related to the retrospective study design, we believe that, in the absence of a randomized clinical trial, our findings should be considered when recommending local ablative therapy for localized unresectable HCC.
Open Treatment of Olecranon Fractures with Plate Fixation
Sems, S.A. , Steinmann, Scott P. , Sems, S Andrew, Adams, Julie E.

Mayo Clinic

JBJS Essential Surgical Techniques | January 10, 2018 | Volume: 8 | Issue: 1 | Pages: e1

10.2106/jbjs.st.15.00012 | PMID 30233973 Get It

Fractures of the olecranon are sometimes difficult to treat. The steps for operative plate fixation of olecranon fractures consist of (1) a dorsal incision, (2) exposure using full-thickness flaps, (3) removal of hematoma from the fracture site, (4) fracture reduction, (5) provisional fixation, (6) plate application, (7) proximal fixation, (8) distal fixation, and (9) layered wound closure. Although this is generally a straightforward procedure, several specific steps may make fixation easier and improve outcomes. Outcomes following olecranon fracture fixation are generally good. Patients should expect some loss of terminal extension and a potential for symptoms related to implant prominence, especially in slender patients. Ulnar nerve symptoms are unusual but possible.
The Evolving Treatment of Peripheral Arterial Disease through Guideline-Directed Recommendations
Morcos, Ramez , Louka, Boshra, Esser, Heidi, Shamoun, Fadi , Misra, Sanjay , Tseng, Andrew , Misra, Sanjay , Tseng, Andrew S. , Misra, Sanjay, McBane, Robert D.

Mayo Clinic

Journal of Clinical Medicine | January 9, 2018 | Volume: 7 | Issue: 1 | Pages: 9

10.3390/jcm7010009 | PMID 29315259 Get It

Peripheral arterial disease (PAD) refers to partial or complete occlusion of one or more non-coronary arteries that leads to compromised blood flow and ischemia. Numerous processes are involved in arterial stenosis, however, atherosclerosis remains the most common etiology. PAD constitutes a major health economic problem, and it is estimated that over 200 million people around the world suffer from PAD, with at least 20% having some degree of claudication. The purpose of this review is to compare and contrast the guidelines on PAD published in 2005, 2011 and 2016 in terms of new recommendations and level of evidence for practicing clinicians.
The acute effects of a multi-ingredient pre-workout supplement on resting energy expenditure and exercise performance in recreationally active females
Camic, Clayton L., Doberstein, Scott, Erickson, Jacob L. , Jagim, Andrew R. , Jagim, Andrew R , Cameron, Michael

Mayo Clinic

Journal of the International Society of Sports Nutrition | January 5, 2018 | Volume: 15 | Issue: 1 | Pages: No page available

10.1186/s12970-017-0206-7 | PMID 29311763 Get It

Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade
Samson, Adel , Scott, Karen J. , Taggart, David J. , Wilson, Erica , Nuovo, Gerard J. , Thomson, Simon , Mathew, Ryan , Fuller, Martin, Kottke, Timothy, Thompson, Jill , Ilett, Elizabeth J. , Cockle, Julia , Hille, Philip van, Sivakumar, Gnanamurthy, Polson, Euan S. , Turnbull, Samantha , Appleton, Elizabeth , Migneco, G , Rose, Ailsa , Coffey, Matthew, Beirne, Deborah , Collinson, Fiona , Ralph, Christy , Anthoney, Alan , Twelves, Christopher , Furness, Andrew J.S. , Quezada, Sergio A. , Wurdak, Heiko , Errington‐Mais, Fiona , Pandha, Hardev , Harrington, Kevin J. , Selby, Peter J. , Vile, Richard G. , Griffin, Stephen , Stead, Lucy F. , Short, Susan , Melcher, Alan , Taggart, David , Wilson, Erica , Nuovo, Gerard J , Thomson, Simon , Mathew, Ryan K , Kottke, Timothy J, Thompson, Jill M, Ilett, Elizabeth J , Cockle, Julia V , Turnbull, Samantha J , Rose, Ailsa S , Beirne, Deborah A , Ralph, Christy , Alan Anthoney, D , Quezada, Sergio A , Wurdak, Heiko , Errington-Mais, Fiona , Selby, Peter J , Griffin, Stephen , Stead, Lucy F , Short, Susan C , Melcher, Alan A , Harrington, Kevin , West, Emma J. , Corns, Robert A. , Appleton, Elizabeth

Mayo Clinic

Science Translational Medicine | January 3, 2018 | Volume: 10 | Issue: 422 | Pages: No page available

10.1126/scitranslmed.aam7577 | PMID 29298869 Get It

Intravenous infusion of oncolytic reovirus in patients leads to infection of brain tumors, infiltration by cytotoxic T cells, and up-regulation of PD-L1.
Low‐grade fibromyxoid sarcoma arising within the median nerve
Swanson, Amy A. , Giannini, Caterina , Folpe, Andrew L. , Dyke, Daniel L. Van , Amrami, Kimberly K. , Michalak, William A., Van Dyke, Daniel L, Vaubel, Rachael A. , Giannini, Caterina

Mayo Clinic

Neuropathology | January 3, 2018 | Volume: 38 | Issue: 3 | Pages: 309-314

10.1111/neup.12453 | PMID 29314300 Get It

We report a case of low‐grade fibromyxoid sarcoma arising within the median nerve. A 31‐year‐old woman presented with symptoms of carpal tunnel syndrome and an enlarging mass in her right palm over 1 year. MRI demonstrated a mass associated with the right median nerve with solid and cystic components. At surgery, the mass was located within the epineurium, could be bluntly dissected from the nerve fascicles, and was suspected to be a schwannoma. A 3.4 cm, tan‐pink, glistening, smooth, homogenous mass was submitted to pathology. Microscopically, the tumor was a solid and cystic circumscribed nodule with a dense fibrous pseudocapsule. The tumor cells were uniformly bland and spindle‐shaped, with small, hyperchromatic oval nuclei and were embedded in an alternating fibrous and myxoid stroma with a prominent curvilinear vasculature and perivascular sclerosis. The differential diagnosis for this lesion included myxoid neurofibroma, schwannoma, soft tissue perineurioma, low‐grade malignant peripheral nerve sheath tumor and low‐grade fibromyxoid sarcoma. The tumor cells expressed MUC4, GLUT‐1, and vimentin and were negative for S‐100 protein, epithelial membrane antigen, smooth muscle actin, desmin, claudin‐1, neurofilament and SOX10. Fluorescence in situ hybridization, with a break‐apart probe strategy, demonstrated FUS rearrangement, consistent in this morphological context with the low‐grade fibromyxoid sarcoma‐associated FUS‐CREB3L2 or FUS‐CREB3L1 fusions. Low‐grade fibromyxoid sarcoma is exceptionally rare in the peripheral nerve, with only a single previously reported case. Nonetheless, as our case illustrates, this entity must be included in the differential diagnosis of unusual intraneural mesenchymal tumors. As in all other locations, intraneural low‐grade fibromyxoid sarcomas should be excised with negative margins. Patients with this disease require long‐term clinical follow‐up, given this tumor's propensity for very late distant metastases to the lungs and other sites.